Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether 5 mL of 0.5% preservative-free bupivacaine may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive 5 mL of 0.5% preservative-free bupivacaine, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Canada.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: March 30, 2024
Recruitment status
Enrolling By Invitation
Enrollment listed in the registry
54
Sponsor
The Royal's Institute of Mental Health Research
Sponsor type
Research institute
Study type
Behavioral
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 18 Years to 69 Years
Official registry ID
NCT05427500
Official title
Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05427500. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Canada · 1 site
The Royal Ottawa Mental Health Centre
Ottawa, Ontario
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: The most common treatment for Posttraumatic Stress Disorder (PTSD) is trauma-focused therapy and/or prescription of medication(s). However, these treatments may not directly reduce symptoms associated with PTSD, making it difficult for patients to be treated for this condition. The study team can confirm the exact objective and what it means for you.
What is a behavioral study?
This appears to be a behavioral / psychological / psychosocial study involving 5 mL of 0.5% preservative-free bupivacaine. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 69 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may take part in sessions or exercises related to habits, thoughts, emotions, or behaviors. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Could this study affect my mood, habits, motivation, or stress?
Behavioral studies can involve habits, emotions, motivation, stress, sleep, or ways of thinking. Ask whether the intervention could affect your mood or stress, and who to contact if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by The Royal's Institute of Mental Health Research, which appears to be a research institute. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists enrollment by invitation. This is not open recruitment; contact the research team to understand who may be invited.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
